Last edition
News about "GC4006A vaccine candidate"
GC Biopharma Wins IND Approval in Korea for Phase I COVID-19 mRNA Vaccine Trial
GC Biopharma has received IND approval in Korea to initiate a Phase I clinical trial of its COVID-19 mRNA vaccine, marking a key step in advancing its mRNA platform, with plans to submit a Phase II IND in the second half of 2026.
GC4006A Vaccine Candidate | 24/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members